Peps
What is Modified GRF 1-29?
Modified GRF 1-29 is a label used for modified growth-hormone-releasing-factor fragments, often described by sellers as “CJC no DAC.” The selected primary study concerns albumin-binding conjugates rather than a confirmed DAC-free preparation.
Biological role or research focus
GRF analogue identity and hormone signaling.
These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
Names you may encounter
Mod GRF 1-29 · CJC-1295 no DAC · CJC no DAC
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Modified GRF fragment label; DAC-free preparation requires confirmation
- Research focus
- GRF analogue identity and hormone signaling
- Featured evidence
- Related conjugate · Animal and cell study
- Source check
- October 4, 2026
Biology & proposed mechanism
The paper tested GRF-receptor activity and engineered albumin binding to extend exposure. Removing the albumin-binding component changes the intervention and invalidates direct transfer of its pharmacokinetics.
Research context & identity
This page makes the distinction between modified fragments, unmodified sermorelin, and DAC-containing CJC-1295 explicit. A catalog nickname is not a complete sequence definition.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related conjugate · Animal and cell study · 2005
Albumin-binding GRF conjugates and CJC-1295
What did this publication test, and what did it find?
- Population / model
- Cultured rat anterior-pituitary cells and male rats.
- Study design
- Synthesis and testing of maleimido GRF derivatives, albumin conjugation, hormone-release assays, and rat pharmacokinetic measurements.
- Main finding
- The conjugates remained active in hormone-release experiments. The selected CJC-1295 conjugate showed extended circulating exposure and albumin association.
- Limits & context
- These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 1 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Glycine-modified growth hormone secretagogues identified in seized doping material. ↗
Drug testing and analysis · 2019 Feb · Journal Article
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
A hormone-release response is not proof of clinical benefit or safe long-term endocrine stimulation.
Evidence boundaries
These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
CJC 1295 & Ipamorelin Blend (10mg) (No DAC)
BioLongevity Labs · Vendor-labeled research use only
$99.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
CJC-1295 (NO DAC) (10 mg)
American Peptides · Vendor-labeled research use only
$110.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
CJC-1295 No DAC (5 mg / 10 mg)
PSPeptides · Vendor-labeled research use only
$35.99–$59.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Can CJC-1295 with DAC half-life findings be assigned to “no DAC”?
- What material, population, and route were actually studied?
- These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can CJC-1295 with DAC half-life findings be assigned to “no DAC”?
No. The albumin-binding modification is central to the cited paper’s prolonged exposure. The DAC-free product requires its own identity and evidence.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.